GB201813178D0 - Cell - Google Patents

Cell

Info

Publication number
GB201813178D0
GB201813178D0 GBGB1813178.9A GB201813178A GB201813178D0 GB 201813178 D0 GB201813178 D0 GB 201813178D0 GB 201813178 A GB201813178 A GB 201813178A GB 201813178 D0 GB201813178 D0 GB 201813178D0
Authority
GB
United Kingdom
Prior art keywords
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1813178.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Priority to GBGB1813178.9A priority Critical patent/GB201813178D0/en
Publication of GB201813178D0 publication Critical patent/GB201813178D0/en
Priority to CN202411247931.1A priority patent/CN118909124A/zh
Priority to CN202411248012.6A priority patent/CN118878688A/zh
Priority to AU2019321066A priority patent/AU2019321066B2/en
Priority to CN201980053953.5A priority patent/CN112566941B/zh
Priority to CA3109752A priority patent/CA3109752A1/en
Priority to CN202411248075.1A priority patent/CN118930653A/zh
Priority to EP19758458.4A priority patent/EP3837284A1/en
Priority to JP2021507552A priority patent/JP7416762B2/ja
Priority to US17/268,328 priority patent/US20230330139A1/en
Priority to PCT/GB2019/052275 priority patent/WO2020035676A1/en
Priority to JP2023182454A priority patent/JP2023178408A/ja
Priority to US19/021,501 priority patent/US20250381224A1/en
Priority to AU2026203095A priority patent/AU2026203095A1/en
Priority to AU2026203096A priority patent/AU2026203096A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4219—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1813178.9A 2018-08-13 2018-08-13 Cell Ceased GB201813178D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB1813178.9A GB201813178D0 (en) 2018-08-13 2018-08-13 Cell
PCT/GB2019/052275 WO2020035676A1 (en) 2018-08-13 2019-08-13 Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3
CN202411248075.1A CN118930653A (zh) 2018-08-13 2019-08-13 包含抗cd33，抗cll1和至少一个另外的抗cd123和/或flt3 car的car t细胞
JP2021507552A JP7416762B2 (ja) 2018-08-13 2019-08-13 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞
AU2019321066A AU2019321066B2 (en) 2018-08-13 2019-08-13 CAR T-cells comprising an anti CD33, an anti CLL1 and at least one further CAR anti CD123 and/or FLT3
CN201980053953.5A CN112566941B (zh) 2018-08-13 2019-08-13 包含抗cd33，抗cll1和至少一个另外的抗cd123和/或flt3 car的car t细胞
CA3109752A CA3109752A1 (en) 2018-08-13 2019-08-13 Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3
CN202411247931.1A CN118909124A (zh) 2018-08-13 2019-08-13 包含抗cd33，抗cll1和至少一个另外的抗cd123和/或flt3 car的car t细胞
EP19758458.4A EP3837284A1 (en) 2018-08-13 2019-08-13 Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3
CN202411248012.6A CN118878688A (zh) 2018-08-13 2019-08-13 包含抗cd33，抗cll1和至少一个另外的抗cd123和/或flt3 car的car t细胞
US17/268,328 US20230330139A1 (en) 2018-08-13 2019-08-13 Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3
JP2023182454A JP2023178408A (ja) 2018-08-13 2023-10-24 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞
US19/021,501 US20250381224A1 (en) 2018-08-13 2025-01-15 Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3
AU2026203095A AU2026203095A1 (en) 2018-08-13 2026-04-24 Cell
AU2026203096A AU2026203096A1 (en) 2018-08-13 2026-04-24 Cell

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1813178.9A GB201813178D0 (en) 2018-08-13 2018-08-13 Cell

Publications (1)

Publication Number Publication Date
GB201813178D0 true GB201813178D0 (en) 2018-09-26

Family

ID=63667077

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1813178.9A Ceased GB201813178D0 (en) 2018-08-13 2018-08-13 Cell

Country Status (8)

Country Link
US (2) US20230330139A1 (enExample)
EP (1) EP3837284A1 (enExample)
JP (2) JP7416762B2 (enExample)
CN (4) CN118930653A (enExample)
AU (3) AU2019321066B2 (enExample)
CA (1) CA3109752A1 (enExample)
GB (1) GB201813178D0 (enExample)
WO (1) WO2020035676A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7711945B2 (ja) * 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
BR112022016550A2 (pt) * 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
WO2022099175A1 (en) * 2020-11-09 2022-05-12 2Seventy Bio, Inc. Cd33 targeted immunotherapies
CN113248621B (zh) * 2020-12-11 2022-11-04 广州百暨基因科技有限公司 Cll1和cd33双靶点嵌合抗原受体及其应用
CN113045658B (zh) 2020-12-11 2021-12-24 广州百暨基因科技有限公司 抗cll1抗体及其应用
CN113234169B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
CN115197330B (zh) * 2021-04-14 2023-04-28 广州百暨基因科技有限公司 同时靶向cll1和cd33的嵌合抗原受体及其应用
CN117715935A (zh) * 2021-07-30 2024-03-15 南京传奇生物科技有限公司 抗cd33抗体及其用途
EP4377353A4 (en) * 2021-07-30 2025-12-17 Nanjing Legend Biotech Co Ltd ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF
CN116018351A (zh) * 2021-08-16 2023-04-25 上海优替济生生物医药有限公司 靶向cd123的抗体、嵌合抗原受体及其用途
CN116063490A (zh) * 2021-09-07 2023-05-05 苏州晟济药业有限公司 一种vhh抗体或其抗原片段的突变体及其用途
WO2023205876A1 (en) * 2022-04-29 2023-11-02 Novobind Livestock Therapeutics Inc. Antibodies against disease causing agents of plants and uses thereof
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
CN116239690B (zh) * 2022-12-27 2024-01-30 四川大学 一种抗cd123的纳米抗体及其制备方法和应用
CN117482246B (zh) * 2022-12-30 2024-10-15 英百瑞(杭州)生物医药有限公司 抗cd33/cll1双特异性抗体-自然杀伤细胞偶联物及其用途
CN117964760B (zh) * 2023-12-21 2024-09-03 四川大学华西医院 抗人cll1/cd3的双特异性抗体及其应用
WO2026015644A1 (en) * 2024-07-10 2026-01-15 The Trustees Of The University Of Pennsylvania Cadherin-17 targeting antigen biding polypeptides, chimeric antigen receptors, car-t cells and methods of treating cadherin-17 positive cancers
GB202414617D0 (en) 2024-10-04 2024-11-20 Chancellor Masters And Scholars Of The Univ Of Oxford Immunotherapy
CN122234223A (zh) * 2026-05-21 2026-06-19 济南微生态生物医学省实验室 一种靶向nk1r的纳米抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
EP3858379A1 (en) 2013-11-21 2021-08-04 Autolus Limited Cell
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
BR112017000939A2 (pt) * 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
EP3250602A1 (en) * 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
WO2016142532A1 (en) * 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP6894430B2 (ja) * 2015-08-24 2021-06-30 セレクティスＣｅｌｌｅｃｔｉｓ 統合された制御機能を有するキメラ抗原受容体
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
US20230071283A1 (en) * 2016-04-15 2023-03-09 Aimee S. Payne Compositions and methods for selective protein expression
GB201607968D0 (en) * 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
PL3896091T3 (pl) * 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania

Also Published As

Publication number Publication date
EP3837284A1 (en) 2021-06-23
WO2020035676A1 (en) 2020-02-20
CN118909124A (zh) 2024-11-08
CN112566941B (zh) 2024-12-31
US20250381224A1 (en) 2025-12-18
AU2026203095A1 (en) 2026-05-14
JP2021533766A (ja) 2021-12-09
AU2026203096A1 (en) 2026-05-14
CN118930653A (zh) 2024-11-12
JP7416762B2 (ja) 2024-01-17
CN118878688A (zh) 2024-11-01
CN112566941A (zh) 2021-03-26
US20230330139A1 (en) 2023-10-19
AU2019321066A1 (en) 2021-03-04
CA3109752A1 (en) 2020-02-20
JP2023178408A (ja) 2023-12-14
AU2019321066B2 (en) 2026-06-04

Similar Documents

Publication Publication Date Title
CA188076S (en) Battery
IL273915A (en) cell
GB201819540D0 (en) T cell modification
GB2577261B (en) Battery
GB2577114B (en) Battery
PL3654417T3 (pl) Bateria
GB201713078D0 (en) T Cell Modification
GB201714718D0 (en) Cell
GB201707779D0 (en) Cell
GB201901307D0 (en) Electrolytes
GB201803079D0 (en) Cell
HUE069716T2 (hu) Akkumulátor
GB201720949D0 (en) Cell
GB201707783D0 (en) Cell
CA201678S (en) Battery
GB201814254D0 (en) Pe959147gb
GB201915526D0 (en) Modified cell
GB201718697D0 (en) Cell
GB201904971D0 (en) Cell
GB201815190D0 (en) Battery compartent
GB201816399D0 (en) Cell
GB201807693D0 (en) Cell
GB201906202D0 (en) Cell
GB201805918D0 (en) Cell
GB201818625D0 (en) Battery

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)